Biolife Sciences Stock Analysis
| BLFE Stock | USD 0.0001 0.00 0.00% |
BioLife Sciences' financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. BioLife Sciences' financial risk is the risk to BioLife Sciences stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Given that BioLife Sciences' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which BioLife Sciences is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of BioLife Sciences to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, BioLife Sciences is said to be less leveraged. If creditors hold a majority of BioLife Sciences' assets, the Company is said to be highly leveraged.
BioLife Sciences is overvalued with Real Value of 8.4E-5 and Hype Value of 1.0E-4. The main objective of BioLife Sciences pink sheet analysis is to determine its intrinsic value, which is an estimate of what BioLife Sciences is worth, separate from its market price. There are two main types of BioLife Sciences' stock analysis: fundamental analysis and technical analysis.
The BioLife Sciences pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and BioLife Sciences' ongoing operational relationships across important fundamental and technical indicators.
BioLife |
BioLife Pink Sheet Analysis Notes
The company recorded a loss per share of 0.01. BioLife Sciences last dividend was issued on the 23rd of July 2018. The entity had 1:75 split on the 23rd of July 2018. Bio Life Sciences Corp. develops, licenses, and distributes antibacterial products and non-contact human temperature screening technology. Bio Life Sciences Corp. was incorporated in 2018 and is based in Mississauga, Canada. Biolife Sciences operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 3 people.The quote for BioLife Sciences is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on BioLife Sciences please contact Justin Four at 833-919-1037 or go to https://www.biolifesciences.com.BioLife Sciences Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more pink sheets at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. BioLife Sciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding BioLife Sciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| BioLife Sciences generated a negative expected return over the last 90 days | |
| BioLife Sciences has some characteristics of a very speculative penny stock | |
| BioLife Sciences has high likelihood to experience some financial distress in the next 2 years | |
| BioLife Sciences currently holds 398 K in liabilities. BioLife Sciences has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioLife Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, BioLife Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioLife Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioLife to invest in growth at high rates of return. When we think about BioLife Sciences' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (456.87 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| BioLife Sciences currently holds about 15.62 K in cash with (106.55 K) of positive cash flow from operations. |
BioLife Sciences Thematic Classifications
In addition to having BioLife Sciences pink sheet in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | PennyStrong penny or near-penny equities |
BioLife Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 11.45 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioLife Sciences's market, we take the total number of its shares issued and multiply it by BioLife Sciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
BioLife Sciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.BioLife Sciences Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. BioLife Sciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for BioLife Sciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
BioLife Sciences Outstanding Bonds
BioLife Sciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioLife Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioLife bonds can be classified according to their maturity, which is the date when BioLife Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
BioLife Sciences Debt to Cash Allocation
Many companies such as BioLife Sciences, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
BioLife Sciences currently holds 398 K in liabilities. BioLife Sciences has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioLife Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, BioLife Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioLife Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioLife to invest in growth at high rates of return. When we think about BioLife Sciences' use of debt, we should always consider it together with cash and equity.BioLife Sciences Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the BioLife Sciences' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of BioLife Sciences, which in turn will lower the firm's financial flexibility.BioLife Sciences Corporate Bonds Issued
Most BioLife bonds can be classified according to their maturity, which is the date when BioLife Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About BioLife Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how BioLife Sciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioLife shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as BioLife Sciences. By using and applying BioLife Pink Sheet analysis, traders can create a robust methodology for identifying BioLife entry and exit points for their positions.
Bio Life Sciences Corp. develops, licenses, and distributes antibacterial products and non-contact human temperature screening technology. Bio Life Sciences Corp. was incorporated in 2018 and is based in Mississauga, Canada. Biolife Sciences operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 3 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding BioLife Sciences to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Complementary Tools for BioLife Pink Sheet analysis
When running BioLife Sciences' price analysis, check to measure BioLife Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Sciences is operating at the current time. Most of BioLife Sciences' value examination focuses on studying past and present price action to predict the probability of BioLife Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Sciences' price. Additionally, you may evaluate how the addition of BioLife Sciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |